Can an adult with chronic myeloid leukemia have an extramedullary mass persisting for 18 months without disease progression?

Can an Adult with CML Have an Extramedullary Mass for 18 Months Without Progressing?

Yes, an adult with CML can have an extramedullary mass persist for 18 months without disease progression, particularly when the mass consists of mature granulocytes during chronic phase rather than blasts, though this requires tissue confirmation and close monitoring as it represents an uncommon but recognized manifestation.

Key Clinical Context

Extramedullary involvement in CML traditionally signals blast phase progression, but emerging evidence demonstrates that extramedullary masses composed of mature granulocytes can occur during chronic phase without representing disease progression 1, 2, 3.

Critical Distinction: Composition Determines Prognosis

The cellular composition of the extramedullary mass is the decisive factor:

• Mature granulocytes (extramedullary hematopoiesis): Compatible with chronic phase CML, can persist without progression, responds to TKI therapy alone 1, 2, 3
• Immature blasts (myeloid sarcoma): Indicates blast phase or accelerated disease, carries poor prognosis with median survival of 16 months despite aggressive therapy 4

A 2024 case report documented an extramedullary mass of mature granulocytes that completely resolved with dasatinib alone, without antibiotics or drainage, confirming this can occur in chronic phase 1. Another 2016 case showed multiple subcutaneous masses from extramedullary hematopoiesis in chronic phase CML that disappeared within 1 month of dasatinib treatment 2.

Diagnostic Algorithm

Immediate Steps Required:

1. Obtain tissue biopsy - This is non-negotiable. CT-guided needle biopsy is sufficient 1
2. Pathological examination must include:
   • Differentiation stage of granulocytes (mature vs. immature)
   • Immunohistochemistry: CD34, p53 (negative in extramedullary hematopoiesis) 2
   • BCR-ABL1 FISH to confirm clonality 3
3. Concurrent bone marrow assessment:
   • Blast percentage (<10% supports chronic phase per 2025 ELN guidelines) 5
   • Cytogenetics for high-risk additional chromosomal abnormalities 5
   • BCR-ABL1 transcript levels 6

Common Pitfall to Avoid:

Do not assume extramedullary disease equals blast crisis without tissue confirmation. The 2024 case report explicitly states: "the clinical course of the current case highlights the importance of prompt biopsy, pathological examination and the early initiation of appropriate treatment" 1. Extramedullary hematopoiesis with mature cells mimics infection or other conditions and requires different management than myeloid sarcoma.

Disease Phase Classification

The 2025 ELN guidelines now recognize CML as a biphasic disease (chronic phase vs. blast phase), with blast phase defined as >20% blasts 5. Patients can present with high-risk features without being in blast phase 5. The WHO 2022 classification acknowledges that changes predictive of impending progression may impact treatment choices but don't automatically reclassify disease phase 5.

Management Based on Mass Composition

If Mature Granulocytes (Extramedullary Hematopoiesis):

• Continue or initiate TKI therapy - Second-generation TKIs (dasatinib, nilotinib, bosutinib) are preferred 1, 2
• Add radiation therapy only if symptomatic (pain, neuropathy from mass effect) 2
• Monitor molecular response every 3 months per NCCN guidelines 6
• Expected outcome: Complete resolution of mass within 1-2 months 1, 2

If Immature Blasts (Myeloid Sarcoma):

• This represents blast phase - requires aggressive therapy
• Consider allogeneic stem cell transplantation if eligible, as this provides the longest survival 4
• Prognosis is poor: median survival 16 months despite treatment 4

Monitoring Strategy for Stable Extramedullary Disease

For a mass persisting 18 months in chronic phase:

1. Verify chronic phase status: BCR-ABL1 transcripts should be ≤10% at 3 months, ≤1% at 12 months for optimal response 6
2. Assess for high-risk additional chromosomal abnormalities (major route: +8, +Ph, i(17q), +19, +17, +21; minor route: -7/7q-, 11q23, 3q26.2) as these predict progression 5
3. Consider TKI penetration issues: CNS and some extramedullary sites have variable TKI penetration 4
4. If molecular response is suboptimal, switch TKI rather than assuming progression 2

Prognostic Implications

The presence of extramedullary disease at diagnosis, even with mature cells, may indicate more aggressive biology 2. The 2016 case report notes "extramedullary hematopoiesis in the early stages of CML is uncommon" and emphasizes "the need to elucidate the pathogenesis" 2. However, with appropriate TKI therapy, complete resolution is achievable and patients can achieve complete cytogenetic response 1, 7.

Bottom line: An 18-month persistent extramedullary mass in chronic phase CML is possible if composed of mature granulocytes, but requires tissue confirmation, appropriate TKI therapy, and vigilant monitoring for molecular response and potential progression.